Histamine and cytokine therapy

Acta Oncologica

Volumn 37, Issue 4, 1998, Pages 347-353

  Hellstrand, Kristoffer ^a   Hermodsson, Svante ^a   Naredi, Peter ^a   Mellqvist, Ulf Henrik ^a   Brune, Mats ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; CYTOKINE; HISTAMINE; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; EFFECTOR CELL; HUMAN; IMMUNOTHERAPY; KILLER CELL; MELANOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0031928220     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430566     Document Type: Article

References (40)

1. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-70.
2. Mellstedt H, Frodin JE, Ragnhammar P, et al. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 1991; 30: 923-31.
3. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-6.
4. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-8.
5. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5610-2.
6. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13.
7. Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61: 765-72.
8. Kiessling R, Kono K, Petersson M, Wasserman K. Immunosuppression in human tumor host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 1996; 18: 227-42.
9. Bottazzi B, Walter S, Govino D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-5.
10. Hellstrand K, Hermodsson S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990; 92: 379-89.
11. Hellstrand K, Kylefjord H, Asea A, Hermodsson S. Regulation of the NK-cell response to IFN-α by biogenic amines. J Interferon Res 1992; 12: 199-206.
12. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994; 153: 4940-7.
13. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42-7.
14. Hellstrand K, Hermodsson S. Histamine H2 receptor mediated regulation of human natural killer cell cytotoxicity. J Immunol 1986; 137: 656-60.
15. Lynch NR, Salomon JC. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst 1977; 58: 1093-8.
16. Burtin C, Scheinmann P, Salomon JC, Lespinats G, Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54-60.
17. Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N′-nitro-N-nitrosoguanidine. J Natl Cancer Inst 1986; 76: 277-81.
18. 1C receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions 1994; 41: 118-20.
19. dellaRovere F, Broccio G, Granata A, Fimiani V. In vivo experimental demonstration that hyperhistaminism counteracts tumor growth. Oncol Reports 1994; 1: 175-7.
20. Gifford RR, Ferguson RM, Voss BV. Cimetidine reduction of tumour formation in mice. Lancet 1981; 8221: 638-40.
21. Gorczynski RM, Kennedy M, Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol 1985; 134: 4261-6.
22. Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 1990; 145: 4365-70.
23. Caignard A, Martin M, Reisser D, Thomas B, Martin F. Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer 1984; 50: 661-5.
24. Anderson LM, Giner-Sorolla A, Haller IM, Budinger JM. Effects of cimetidine, nitrite, cimetidine plus nitrite, and nitrosocimetidine on tumors in mice following transplacental plus chronic lifetime exposure. Cancer Res 1985; 45: 3561-6.
25. Mandanas R, Schultz S, Scullin D, Einhorn LH. Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. Am J Clin Oncol 1991; 14: 397-9.
26. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3: 977-81.
27. Links M, Clingan PR, Phadke K, et al. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol. 1995; 21: 523-5.
28. Wotherspoon HA, Anderson JR, Morran CG, McArdle CS. Randomized trial of an H2-receptor antagonist in gastric cancer. Br J Surg 1997; 84: 1168-9.
29. Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365-441.
30. Hellstrand K, Hermodsson S, Brune M, et al. Histamine in cancer immunotherapy. Scand J Clin Lab Invest 1997; 57: 193-202.
31. Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer-cell-mediated clearance of tumor cells in mice. Scand J Immunol 1996; 43: 9-15.
32. Oldham RK, Blumenschein G, Schwartzberg L. Combination biotherapy utilizing interleukin-2 and a interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992; 4: 4-9.
33. Hellstrand K, Naredi P, Lindnér P, et al. Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol Immunother 1994; 39: 416-9.
34. Swansbury GJ, Lawler SD, Alimena G, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1-7.
35. Thalhammer F, Geissler K, Jager U, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216-22.
36. Hellstrand K, Mellqvist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997 (in press).
37. Shepherd JD, Jacky E, Grathwohl A, et al. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994; S87: 205.
38. Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271-9.
39. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996; 92: 620-6.
40. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K. NK-cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996; 57: 312-9.